Key Focus for Hims & Hers Health Investors

By Emilio Sanchez • Friday, February 21 10:07 • Permanent Link

Hims & Hers Health marked a -21.9% change today, compared to -0.0% for the S&P 500. Is it a good value at today's price of $51.89? Only an in-depth analysis can answer that question, but here are some facts that can give you an idea:

Hims & Hers Health, Inc. operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally.
Hims & Hers Health belongs to the Health Care sector, which has an average price to earnings (P/E) ratio of 26.07 and an average price to book (P/B) of 3.53
The company's P/B ratio is 25.69
Hims & Hers Health has a trailing 12 month Price to Earnings (P/E) ratio of 117.9 based on its trailing 12 month price to earnings (EPS) of $0.44 per share
Its forward P/E ratio is 112.8, based on its forward earnings per share (EPS) of $0.46
Over the last four years, Hims & Hers Health has averaged free cash flows of $-17523400.0, which on average grew 24.7%
HIMS's gross profit margins have averaged 72.6 % over the last four years and during this time they had a growth rate of 6.4 % and a coefficient of variability of 23.21 %.
Hims & Hers Health has moved 597.6% over the last year compared to 20.2% for the S&P 500 -- a difference of 577.4%
HIMS has an average analyst rating of hold and is 50.92% away from its mean target price of $34.38 per share

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.